NORMA Contract Research Organisation for Clinical Trials

NORMA conducts clinical trials, phase I–IV, for international pharmaceutical and biotech companies, through a network of subsidiaries in the Nordic and Baltic countries.

Contract research organisation for clinical trials in northern Europe

We work together as an enthusiastic and service-orientated team to deliver outstanding work. Our flexibility and professionalism have earned us recognition among our clients and is reflected in substantial repeat business.

A recent survey of customer perception among our large customers showed that ‘high quality’ and ‘flexibility’ are the primary reasons for choosing NORMA as their monitoring company. In additon, ‘project team devoted to study’ and ‘geographic reach / presence’ are important factors.

The working climate at NORMAS’s offices is positive and friendly and we strive to keep a low staff turnover.

CRO for clinical trials in various therapeutic areas

NORMA has over 90 employees, including experienced project managers, clinical research associates and clinical trials assistants. NORMA has 19 years of experience and has participated in more than 300 clinical trials across a wide range of therapeutic areas, including:

  • Cardiovascular disorders: AMI, angina pectoris, hypertension, PAD and ACS
  • CNS: depression, schizophrenia, Alzheimer’s dementia, epilepsy, MS, Parkinson’s disease and pain
  • Dermatology: psoriasis and PLE / PMLE
  • Endocrinology: diabetes, HRT, oral contraceptives and osteoporosis
  • Infection: HIV, vaccines and herpes zoster
  • Gastrointestinal disorders: ulcerative colitis, Crohn’s disease and collagenous colitis
  • Oncology: breast cancer, prostate cancer, head-and-neck, leukaemia, solid tumours and malignant melanoma
  • Immunology: arthritis and osteoarthrosis
  • Medical devices: cardiac stents, urethral catheters and suction bags

NORMA has a strong client base with 80% repeat business due to a high level of quality. NORMA has a vast and valid network of potential investigators, and is a flexible and co-operative business partner.

Contract research services for clinical trials

NORMA staff work according to client or NORMA SOPs:

  • Recruitment and evaluation of investigators
  • GCP training of investigators and site staff
  • Submissions to medicines agencies and ethics committees
  • Organisation of investigator meetings
  • Protocol writing
  • CRF design
  • Translations
  • Regular monitoring of phase I-IV trials
  • Reporting to sponsor
  • Medical monitoring
  • Outsourcing of CRAs and CTAs

Contact NORMA

NORMA covers the entire Nordic and Baltic region in northern Europe, with offices in Denmark, Finland, Norway, Sweden, Estonia and Lithuania.

All these countries follow the general EU guidelines for approval of clinical trials; however, there are additional national – or even local – guidelines to follow. The local offices work competently and efficiently according to guidelines to meet and surpass client expectations.

Make an enquiry

NORMA Denmark

Slotsmarken 11

2970 Horshølm



NORMA Images

Products and Services


White Papers

Related Projects

Afinitor Disperz (everolimus) for the Treatment of TSC-Associated Partial-Onset Seizures

Afinitor Disperz® (everolimus) is indicated for the treatment of tuberous sclerosis complex (TSC) associated partial-onset seizures in adult and paediatric patients.

14th June 2018

Lucemyra (lofexidine) for the Management of Opioid Withdrawal Symptoms

Lucemyra™ (lofexidine) is a non-opioid medication indicated for the mitigation of opioid withdrawal symptoms.

25th May 2018

Fasenra (benralizumab) for the Treatment of Asthma

Fasenra (benralizumab) is a monoclonal antibody (mAb) indicated for the treatment of severe eosinophilic asthma in patients aged 12 years and older.

27th March 2018

Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease

Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

15th December 2017

Sublocade™ for the Treatment of Opioid Use Disorder

Sublocade™ (buprenorphine extended-release) is a partial agonist indicated for the treatment of moderate-to-severe opioid use disorder (OUD) in adults.

11th December 2017

Aliqopa (copanlisib) for the Treatment of Relapsed Follicular Lymphoma

Aliqopa (copanlisib) is a novel intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).

22nd September 2017

Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six.

27th July 2017

Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Ligand Pharmaceuticals.

6th July 2017

Truxima (rituximab) for the Treatment of Cancer

ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well as granulomatosis with polyangiitis and microscopic polyangiitis.

8th June 2017

Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).

16th May 2017

Alecensa (alectinib) for the Treatment of ALK-positive Non-small Cell Lung Cancer (NSCLC)

Alecensa (alectinib) is a kinase inhibitor intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

2nd March 2017

Exondys 51 (eteplirsen) for the Treatment of Duchenne Muscular Dystrophy (DMD)

Exondys 51 (eteplirsen) is an injectable solution developed by Sarepta Therapeutics.

20th October 2016

Tagrisso (osimertinib) For the Treatment of EGFR mutation in Non-Small Cell Lung Cancer

Tagrisso (osimertinib) is a once-daily tablet developed by AstraZeneca for the treatment of metastatic epidermal growth factor receptor (EGFR) T790M mutation associated with non-small cell lung cancer (NSCLC).

28th June 2016

Defitelio (defibrotide sodium) for the Treatment of Hepatic Veno-Occlusive Disease

Defitelio (defibrotide sodium) is an injectable drug developed by Jazz Pharmaceuticals, for the treatment of hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome, in adults and children with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).

19th May 2016

Durlaza (aspirin) for Reducing Risk of Cardiovascular Events

Durlaza (aspirin) is a non steroidal anti-inflammatory drug indicated for the prevention of thrombotic events in patients with cardiovascular disease (CVD).

16th September 2015

Press Release

Regional Offices

NORMA Denmark

Slotsmarken 11

2970 Horshølm


NORMA Norway

Ullernchausséen 119

N-0284 Oslo



+47 6752 5800 +47 6752 5801
NORMA Lithuania

J. Galvydzio 3, Room 108

08236 Vilnius



+370 5 27 45 47 5 +370 5 27 45 47 6
NORMA Sweden

Hemvärnsgatan 15, 10 tr.

171 54 Solna



+46 8 5620 0451 +46 8 296 721
NORMA Finland

Rajatorpantie 41 C

01640 Vantaa



+358 9 8520 2140 +358 9 8520 2145
NORMA Estonia

Betooni 9

Tartu 51014



+372 7307 827 +372 7307 828

Go Top